City: New Taipei City

Acer Inc. was founded in 1976 by Stan Shih and is a Taiwan-based global technology company with operations in over 160 countries. Building on its strong foundation in computing and data technologies, Acer has strategically expanded into the biomedical field to develop a next-generation RNA therapeutics platform. Since 2018, the company has focused on personalized cancer vaccines, powered by proprietary AI models for high-precision neoantigen prediction. This AI-driven engine enables rapid identification of clinically relevant targets, significantly accelerating and improving the design of individualized immunotherapies. In 2021, Acer established its mRNA-LNP platform and has since developed a proprietary ionizable lipid, AIL-111, engineered for high delivery efficiency and favorable in vivo performance. This platform enables robust mRNA delivery and serves as the foundation for multiple therapeutic applications. Leveraging this core capability, Acer is advancing a targeted LNP (tLNP) platform for cell-specific delivery, including in vivo CAR-T cell generation, where mRNA is directly delivered to T cells within the body to induce transient CAR expression. This approach has the potential to simplify manufacturing, reduce cost, and improve accessibility compared to conventional ex vivo cell therapies. By integrating AI-driven antigen discovery, proprietary LNP delivery technology, and in vivo cell engineering, Acer is building a scalable and modular platform for next-generation RNA medicines. The company aims to become a key innovator at the intersection of digital technology and biopharmaceutical development, enabling transformative therapies for cancer and beyond.